Replies to post #583007 on NorthWest Biotherapeutics Inc (NWBO)

[Jackxkr]

It appears its just for urethral cancer, we can do others hopefully.

[dstock07734]

Serious adverse reactions occurred in 50% of patients receiving KEYTRUDA in combination with enfortumab vedotin

50% strikes me as a number far too high.